- Home
- ZUMZ vs FULC Comparison
ZUMZ vs FULC Comparison
Compare ZUMZ & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZUMZ
- FULC
- Stock Information
- Founded
- ZUMZ 1978
- FULC 2015
- Country
- ZUMZ United States
- FULC United States
- Employees
- ZUMZ N/A
- FULC N/A
- Industry
- ZUMZ Clothing/Shoe/Accessory Stores
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- ZUMZ Consumer Discretionary
- FULC Health Care
- Exchange
- ZUMZ Nasdaq
- FULC Nasdaq
- Market Cap
- ZUMZ 343.6M
- FULC 372.2M
- IPO Year
- ZUMZ 2005
- FULC 2019
- Fundamental
- Price
- ZUMZ $19.98
- FULC $7.29
- Analyst Decision
- ZUMZ Hold
- FULC Buy
- Analyst Count
- ZUMZ 1
- FULC 8
- Target Price
- ZUMZ $18.00
- FULC $7.13
- AVG Volume (30 Days)
- ZUMZ 261.5K
- FULC 382.4K
- Earning Date
- ZUMZ 09-04-2025
- FULC 11-12-2025
- Dividend Yield
- ZUMZ N/A
- FULC N/A
- EPS Growth
- ZUMZ N/A
- FULC N/A
- EPS
- ZUMZ 0.03
- FULC N/A
- Revenue
- ZUMZ $900,253,000.00
- FULC N/A
- Revenue This Year
- ZUMZ $3.31
- FULC N/A
- Revenue Next Year
- ZUMZ $1.34
- FULC N/A
- P/E Ratio
- ZUMZ $616.67
- FULC N/A
- Revenue Growth
- ZUMZ 1.64
- FULC 2752.05
- 52 Week Low
- ZUMZ $11.31
- FULC $2.32
- 52 Week High
- ZUMZ $24.67
- FULC $8.50
- Technical
- Relative Strength Index (RSI)
- ZUMZ 55.36
- FULC 57.46
- Support Level
- ZUMZ $20.57
- FULC $6.69
- Resistance Level
- ZUMZ $22.15
- FULC $7.50
- Average True Range (ATR)
- ZUMZ 0.70
- FULC 0.40
- MACD
- ZUMZ -1.09
- FULC 0.06
- Stochastic Oscillator
- ZUMZ 90.29
- FULC 62.50
About ZUMZ Zumiez Inc.
Zumiez Inc is a United-States-based specialty retailer engaged in the sale of apparel, footwear, accessories, and hard goods. The company provides merchandise with cultural elements coming from fashion, music, art from action sports, streetwear, and other lifestyles. The company operates under the brands Zumiez, Fast Times, and Blue Tomato, and through both physical stores and websites. The majority of the company's stores are located in the U.S., with the rest in Canada, Australia, and Europe. The U.S. market contributes to the majority of the company's revenue.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.